Vyome (HIND)
Market Price (6/29/2026): $2.14 | Market Cap: $14.3 MilSector: Health Care | Industry: Biotechnology
Vyome (HIND)
Market Price (6/29/2026): $2.14Market Cap: $14.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -61% Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -119%, 3Y Excs Rtn is -153% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1179% Weak revenue growthRev Chg QQuarterly Revenue Change % is -49% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 46% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -80% Key risksHIND key risks include [1] the failure of its lead drug candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -61% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -119%, 3Y Excs Rtn is -153% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1179% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -49% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 46% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -80% |
| Key risksHIND key risks include [1] the failure of its lead drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Vyome (HIND) stock has lost about 35% since 2/28/2026 because of the following key factors:
1. Vyome Holdings reported significantly wider net losses and a substantial revenue decline in fiscal Q1 2026 (ended March 31, 2026). The company recorded a net loss of $985,521 in fiscal Q1 2026, a notable increase from the $293,974 loss in the prior-year period. Concurrently, revenue plummeted to $31,591 in fiscal Q1 2026 from $198,581 a year earlier.
2. Increased operating expenses and a prolonged unprofitability outlook contributed to investor concerns. Operating expenses rose to $1.15 million in fiscal Q1 2026, primarily due to increased investment in clinical-stage programs. Analysts forecast Vyome to remain unprofitable for the next three years, with a projected breakeven not anticipated until 2028, reflecting limited near-term revenue prospects.
Show more
Vyome (HIND) stock has lost about 35% since 2/28/2026 because of the following key factors:
1. Vyome Holdings reported significantly wider net losses and a substantial revenue decline in fiscal Q1 2026 (ended March 31, 2026). The company recorded a net loss of $985,521 in fiscal Q1 2026, a notable increase from the $293,974 loss in the prior-year period. Concurrently, revenue plummeted to $31,591 in fiscal Q1 2026 from $198,581 a year earlier.
2. Increased operating expenses and a prolonged unprofitability outlook contributed to investor concerns. Operating expenses rose to $1.15 million in fiscal Q1 2026, primarily due to increased investment in clinical-stage programs. Analysts forecast Vyome to remain unprofitable for the next three years, with a projected breakeven not anticipated until 2028, reflecting limited near-term revenue prospects.
3. Negative analyst sentiment and significant financial stability concerns impacted the stock. Vyome received a low GF Score™ of 13 out of 100, highlighting substantial financial challenges, particularly in profitability. Additionally, the company's Altman Z-score of -10.44 indicates it is in a "distress zone," suggesting potential bankruptcy risk within two years. This led to analyst consensus shifting to "Hold" and a price target decrease of 23.33% to $11.73 by May 15, 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The -35.9% change in HIND stock from 2/28/2026 to 6/28/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6282026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.37 | 2.16 | -35.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | � | 0.0% |
| Net Income Margin (%) | � | � | 0.0% |
| P/E Multiple | � | � | 0.0% |
| Shares Outstanding (Mil) | 6 | 6 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/28/2026| Return | Correlation | |
|---|---|---|
| HIND | -35.9% | |
| Market (SPY) | 6.6% | 32.9% |
| Sector (XLV) | 0.5% | 30.2% |
Fundamental Drivers
The -58.3% change in HIND stock from 11/30/2025 to 6/28/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6282026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.18 | 2.16 | -58.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | � | 0.0% |
| Net Income Margin (%) | � | � | 0.0% |
| P/E Multiple | � | � | 0.0% |
| Shares Outstanding (Mil) | 6 | 6 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/28/2026| Return | Correlation | |
|---|---|---|
| HIND | -58.3% | |
| Market (SPY) | 7.3% | 21.5% |
| Sector (XLV) | 2.6% | 23.5% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2025 to 6/28/2026| Return | Correlation | |
|---|---|---|
| HIND | ||
| Market (SPY) | 25.1% | 15.9% |
| Sector (XLV) | 23.0% | 20.7% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/28/2026| Return | Correlation | |
|---|---|---|
| HIND | ||
| Market (SPY) | 81.3% | 15.9% |
| Sector (XLV) | 31.9% | 20.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HIND Return | - | - | - | - | -75% | -39% | -85% |
| Peers Return | 19% | -13% | -1% | 74% | 40% | 4% | 157% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| HIND Win Rate | - | - | - | - | 20% | 33% | |
| Peers Win Rate | 53% | 53% | 47% | 52% | 58% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HIND Max Drawdown | - | - | - | - | - | -47% | |
| Peers Max Drawdown | -45% | -44% | -61% | -49% | -48% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARQT, ACRS, VRCA, INCY, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
How Low Can It Go
HIND has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
HIND has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Vyome (HIND)
ReShape Lifesciences Inc. (HIND) is a medical device company dedicated to developing and providing products and services for the management and treatment of obesity and metabolic diseases. The company focuses on offering less invasive solutions compared to traditional surgical procedures, alongside comprehensive patient support programs, to improve health outcomes for individuals struggling with weight-related conditions.
Its product portfolio features several key solutions, including the Lap-Band System, a minimally invasive, long-term treatment for severe obesity that offers an alternative to more invasive gastric surgeries. Additionally, ReShape Lifesciences is developing the ReShape Vest system, an investigational device designed to aid weight loss by wrapping around the stomach without permanent alteration or bypassing parts of the gastrointestinal tract. The company also provides the Obalon Balloon System, a swallowable capsule used for tracking balloon placement, and the ReShapeCare virtual health coaching program, which offers telehealth support for patients undertaking medically managed weight-loss journeys.
ReShape Lifesciences Inc. primarily serves obese and morbidly obese patients, as well as those with metabolic diseases such as type 2 diabetes mellitus, for which it has a preclinical neuromodulation technology in development. The company has a global reach, operating in the United States, Australia, Europe, and other international markets, aiming to provide accessible and effective treatments to a broad patient population.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Key Risks to Vyome (HIND)
The key risks to Vyome (symbol: HIND) are:
- Clinical Development and Regulatory Approval Risk: As a clinical-stage company, Vyome's future success is highly dependent on the successful completion of clinical trials, particularly the ongoing Phase 3 trials for its lead asset VT-1953, and obtaining regulatory approvals from authorities such as the FDA. Failure to achieve positive clinical trial results or secure timely regulatory clearance would significantly impede the company's ability to commercialize its drug candidates and generate revenue.
- Financial Risk and Need for Capital: Developing and commercializing new drug candidates and medical devices is a capital-intensive endeavor. Although Vyome has recently secured funding for its initial Phase 3 trial requirements, the company will likely need substantial additional financing to complete clinical development, advance its pipeline assets, and support commercialization. The predecessor company, ReShape Lifesciences, also faced challenges in maintaining compliance with Nasdaq's minimum stockholders' equity requirements, indicating ongoing financial stability as a critical consideration.
- Market Competition and Acceptance: Vyome operates in highly competitive healthcare sectors, including medical devices for obesity (a legacy from ReShape Lifesciences) and new drug development for immuno-inflammatory conditions and oncology supportive care. There is a risk that Vyome's products, both existing medical devices and new drug candidates, may not achieve sufficient market acceptance or may face intense competition from established or emerging therapies and devices offered by other companies.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Share Repurchases
No significant share repurchases by Vyome Holdings (HIND) or its predecessor, ReShape Lifesciences Inc. (RSLS), have been reported over the last 3-5 years. ReShape Lifesciences Inc. reported "N/A" for share buybacks in fiscal year 2024.
Share Issuance
- Vyome Holdings (HIND) raised approximately $5.29 million by selling 1,089,045 shares at an average price of $5.00 through its At-The-Market (ATM) facility by January 2026 to fund its VT-1953 Phase 3 trial.
- ReShape Lifesciences Inc. (RSLS), prior to its merger, implemented multiple reverse stock splits, including a 1-for-25 split in May 2025 and a 1-for-4 split effective with the merger on August 15, 2025, to maintain NASDAQ listing compliance.
- In April 2025, ReShape Lifesciences Inc. received shareholder approval for an Equity Line of Credit (ELOC) Purchase Agreement from December 2024, allowing it to sell up to $5 million in shares over 36 months to an institutional investor.
Inbound Investments
- ReShape Lifesciences Inc. completed an all-stock merger with Vyome Therapeutics, forming Vyome Holdings, Inc. (HIND), which began trading on Nasdaq on August 15, 2025.
- Vyome Holdings (HIND) utilized an At-The-Market (ATM) facility to raise approximately $5.29 million by January 2026 to fund the initial Phase 3 interim results for its lead drug candidate, VT-1953.
Outbound Investments
- ReShape Lifesciences Inc., as part of the merger agreement, sold substantially all of its assets, including the Lap-Band System, Obalon Gastric Balloon System, and Diabetes Bloc-Stim Neuromodulation System, to Biorad Medisys (or an affiliate), with Biorad assuming most of ReShape's liabilities.
- Vyome Holdings (HIND) launched its AI strategy with the acquisition of MIT startup Oculo, Inc. to develop an AI business unit.
- Vyome, through its 70%-owned subsidiary Livechain Inc., acquired senior, secured convertible debt of Humanyze via an all-stock purchase, valued at approximately $325,000, and is taking over Humanyze's business assets and operations.
Capital Expenditures
- ReShape Lifesciences Inc. reported "N/A" for capital expenditures in fiscal year 2024.
- Vyome Holdings (HIND) is currently funding the estimated costs for its VT-1953 Phase 3 clinical trial, with interim results anticipated in mid-2027.
- For the first quarter of 2025, ReShape Lifesciences Inc.'s research and development expenses decreased by $0.1 million, or 24.8%, to $0.4 million, compared to the same period in the prior year.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.92 |
| Mkt Cap | 2.1 |
| Rev LTM | 226 |
| Op Inc LTM | -0 |
| FCF LTM | 17 |
| FCF 3Y Avg | -41 |
| CFO LTM | 27 |
| CFO 3Y Avg | -41 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 21.5% |
| Rev Chg 3Y Avg | 15.7% |
| Rev Chg Q | 29.0% |
| QoQ Delta Rev Chg LTM | 4.4% |
| Op Inc Chg LTM | 75.6% |
| Op Inc Chg 3Y Avg | -1.4% |
| Op Mgn LTM | -17.8% |
| Op Mgn 3Y Avg | -80.3% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 6.5% |
| CFO/Rev 3Y Avg | -77.3% |
| FCF/Rev LTM | 4.1% |
| FCF/Rev 3Y Avg | -79.1% |
Price Behavior
| Market Price | $2.16 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/06/2016 | |
| Distance from 52W High | -84.6% | |
| 50 Days | 200 Days | |
| DMA Price | $8.08 | $8.08 |
| DMA Trend | down | down |
| Distance from DMA | -73.3% | -73.3% |
| 3M | 1YR | |
| Volatility | 53.5% | 99.0% |
| Downside Capture | 124.27 | 311.39 |
| Upside Capture | 68.32 | 0.83 |
| Correlation (SPY) | 29.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.90 | 0.87 | 1.59 | 1.77 | -0.95 | -0.03 |
| Up Beta | 4.67 | 1.46 | 1.84 | 1.98 | 0.51 | -0.37 |
| Down Beta | -1.61 | -1.27 | 2.13 | -0.18 | -1.18 | 1.67 |
| Up Capture | 133% | 64% | 28% | 119% | -0% | -0% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 14 | 18 | 42 | 75 | 75 |
| Down Capture | -140% | 99% | 230% | 263% | 188% | 95% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 9 | 23 | 39 | 74 | 114 | 114 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIND | |
|---|---|---|---|---|
| HIND | -84.7% | 99.0% | -1.72 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 20.7% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 15.9% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | 1.7% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | -9.2% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | 15.6% |
| Bitcoin (BTCUSD) | -44.2% | 42.5% | -1.25 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIND | |
|---|---|---|---|---|
| HIND | -31.2% | 99.0% | -1.72 | - |
| Sector ETF (XLV) | 7.0% | 14.8% | 0.29 | 20.7% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 15.9% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 1.7% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | -9.2% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | 15.6% |
| Bitcoin (BTCUSD) | 10.9% | 54.0% | 0.39 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIND | |
|---|---|---|---|---|
| HIND | -17.1% | 99.0% | -1.72 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 20.7% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 15.9% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | 1.7% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | -9.2% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 15.6% |
| Bitcoin (BTCUSD) | 54.7% | 66.4% | 0.95 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/29/2026 | -0.4% | -2.1% | |
| 11/19/2025 | 3.5% | 11.5% | -15.8% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 1 | 1 | 1 |
| Median Positive | 3.5% | 11.5% | |
| Median Negative | -0.4% | -2.1% | -15.8% |
| Max Positive | 3.5% | 11.5% | |
| Max Negative | -0.4% | -2.1% | -15.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/29/2026 | -0.4% | -2.1% | |
| 11/19/2025 | 3.5% | 11.5% | -15.8% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 1 | 1 | 1 |
| Median Positive | 3.5% | 11.5% | |
| Median Negative | -0.4% | -2.1% | -15.8% |
| Max Positive | 3.5% | 11.5% | |
| Max Negative | -0.4% | -2.1% | -15.8% |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.